Daniel Petrylak, MD of Yale School of Medicine discusses the role of checkpoint inhibition therapy in urothelial carcinoma cancer at the 2017 Annual Meeting Annual Meeting.
Checkpoint inhibition therapy in urothelial carcinoma cancer
Daniel Petrylak, MD of Yale School of Medicine discusses the role of checkpoint inhibition therapy in urothelial carcinoma cancer at the 2017 Annual Meeting Annual Meeting.